The full content will be available shortly. Thank you for your patience!
Liver transplantation as a treatment option for neuroendocrine liver metastases: a systematic review
- 2026, Volume 94 - Number 5
- Published: October 7, 2026
Liver transplantation as a treatment option for neuroendocrine liver metastases: a systematic review
Isabel Jaén-Torrejimeno 1, 2 
, Diego López-Guerra 1, 2, 3 , Adela Rojas-Holguín 1, 2, 3 , Gerardo Blanco-Fernández 1, 2, 3
1 Servicio de Cirugía Hepatobiliopancreática y Trasplante Hepático, Complejo Hospitalario Universitario de Badajoz, Badajoz, España; 2 Instituto Universitario de Investigación Biosanitaria de Extremadura (INUBE), Universidad de Extremadura, Badajoz, España; 3 Facultad de Medicina y Ciencias de la Salud, Universidad de Extremadura, Badajoz, España
Isabel Jaén-Torrejimeno, Diego López-Guerra, Adela Rojas-Holguín, Gerardo Blanco-Fernández
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondence: Diego López-Guerra. Email: diegolopezg@unex.es
Abstract
Objetive: The aim was to carry out a systematic review of published articles on liver transplantation outcomes in patients with (LM-NET). Methods: We performed a systematic review according to the PRISMA guideline guidelines, using the MEDLINE (PubMed) and Scopus databases to identify published studies. Results: We included 2471 articles after the search, finally selecting 25. We collected data from 1005 patients, with a mean age of 47.9 years, most of them male. The most frequent locations of the primary tumor were the pancreas, followed by the small intestine. The disease-free survival was 25.3 months (14-31) and overall survival 38.5 months (32.5-57.1). Conclusions: Liver transplantation appears to provide a survival benefit in patients with diffuse LM-NET without extrahepatic disease in selected cases.
Keywords: Liver transplant. Neuroendocrine tumor. Liver metastases.
